# A pilot and feasibility study evaluating the association of the use of TCAM on nutritional, biological, and lifestyle indicators in children with ALL undergoing treatment in Guatemala

> **NIH NIH P30** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $168,926

## Abstract

PROJECT SUMMARY
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as
NOT-CA-21-100. The Herbert Irving Comprehensive Cancer Center (HICCC) was designated as a National
Cancer Institute (NCI) Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is the
critical driver of cancer scientific research, clinical trials, innovative patient care, cancer education and training
and community outreach at Columbia University’s Irving Medical Center (CUIMC) and NewYork-Presbyterian
Hospital (NYPH). During the current project period (2014-present), CUIMC and NYPH committed $415M for
the following: (1) new research initiatives in basic, translational, clinical and population sciences with >50
strategic faculty recruitments; (2) new and expanded facilities for laboratory research, dry bench research and
clinical activities; (3) major faculty recruitments; and, (4) support of the HICCC’s administrative core. A major
aspect was the recruitment of Anil K. Rustgi, MD as the HICCC Director in late 2018. Rustgi has the
unequivocal authority over cancer research space and cancer care facilities and accompanying substantial
resources through the transformative Irving Family Trust Gift, further reinforced through his dual roles as
Associate Dean of Oncology (CUIMC) and Chief of Cancer Services (NYPH). Over this project period, there
was a greater focus upon transdisciplinary cross-cutting scientific themes that catalyzed the restructuring of the
scientific research programs encompassing 175 members from 34 Departments and six Schools: Cancer
Genomics and Epigenomics; Tumor Biology and Microenvironment; Precision Oncology and Systems Biology;
and, Cancer Population Science. Importantly, Rustgi created units dedicated to Community Outreach and
Engagement (COE) and Cancer Research Career Enhancement (CRCE) and enhanced the 12 Shared
Resources. The Research Programs engendered impactful science with 3,399 publications of which 626 were
intra-programmatic and 456 were inter-programmatic. Total NCI funding is $26M and cancer-relevant funding
is $92M. The HICCC is requesting CCSG support of $4.1M per year (total DC) for the next project period.

## Key facts

- **NIH application ID:** 10622174
- **Project number:** 3P30CA013696-47S1
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Anil K Rustgi
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $168,926
- **Award type:** 3
- **Project period:** 1997-07-04 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10622174

## Citation

> US National Institutes of Health, RePORTER application 10622174, A pilot and feasibility study evaluating the association of the use of TCAM on nutritional, biological, and lifestyle indicators in children with ALL undergoing treatment in Guatemala (3P30CA013696-47S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10622174. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*